Insulin Aspart vs Lispro: Onset Time

Introduction

Insulin aspart (NovoRapid, NovoLog) and insulin lispro (Humalog) are rapid-acting insulin analogs designed for mealtime (prandial) glucose control. Both were engineered to overcome the limitations of regular human insulin by accelerating absorption from the subcutaneous depot. While their pharmacokinetic profiles are remarkably similar, subtle differences in onset, peak, and duration have clinical implications for dosing strategies.

Molecular Modifications

Insulin Aspart

• Modification: Asparagine (B28) → Aspartic acid
• Effect: Disruption of proline-induced self-association
• Result: Reduced hexamer stability, faster dissociation to monomers
• Commercial form: 100 U/mL (U-100) and 200 U/mL (U-200, Fiasp)

Insulin Lispro

• Modification: Proline (B28) → Lysine; Lysine (B29) → Proline (inversion)
• Effect: Disruption of proline-mediated dimer formation
• Result: Reduced dimer stability, faster monomer release
• Commercial form: 100 U/mL (U-100) and 200 U/mL (U-200, Humalog Junior KwikPen)

Structural Comparison

Parameter	Insulin Aspart	Insulin Lispro
Modification site	B28	B28, B29
Modification type	Single amino acid substitution	Amino acid inversion
Self-association	Reduced hexamers	Reduced dimers
Crystal structure	Monomer-predominant	Monomer-predominant

Pharmacokinetic Profile

Onset Time

Parameter	Insulin Aspart	Insulin Lispro
Onset of action	10–20 minutes	10–20 minutes
Time to 50% of peak	~50 minutes	~50 minutes
Practical onset	10–15 minutes	10–15 minutes

Both agents demonstrate essentially equivalent onset times. The slight numerical differences in published data are not clinically significant at standard doses.

Peak Effect

Parameter	Insulin Aspart	Insulin Lispro
Time to peak	1–2 hours	1–2 hours
Peak concentration (Tmax)	40–60 minutes	40–60 minutes
Peak glucose lowering	1–3 hours	1–3 hours
Peak variability	Low	Low

Duration of Action

Parameter	Insulin Aspart	Insulin Lispro
Duration of action	3–5 hours	3–5 hours
Time to 50% decline from peak	2–3 hours	2–3 hours
Return to baseline glucose	4–6 hours	4–6 hours
Practical dosing interval	≥3 hours	≥3 hours

Pharmacodynamic Profile

Glucose-Lowering Effect

Parameter	Insulin Aspart	Insulin Lispro
Time to maximum glucose lowering	1–2 hours	1–2 hours
Total glucose-lowering effect (AUC)	Equivalent	Equivalent
Duration of glucose lowering	3–5 hours	3–5 hours
Dose-response relationship	Linear (therapeutic range)	Linear (therapeutic range)

Clamp Study Data

Hyperinsulinemic-euglycemic clamp studies demonstrate:

• Glucose infusion rate (GIR) onset: Equivalent between agents (10–20 minutes)
• GIR peak: Equivalent (40–60 minutes)
• GIR duration: Equivalent (3–5 hours)
• GIR AUC: No significant difference

Ultra-Rapid Formulations

Insulin Aspart (Fiasp)

• Modification: Addition of niacinamide (vitamin B3) + L-arginine + L-glutamic acid
• Onset: ~5 minutes (2.5× faster than standard aspart)
• Time to peak: ~45 minutes
• Duration: 3–5 hours
• Clinical benefit: Better postprandial glucose control, reduced injection-meal timing constraints

Insulin Lispro (Lyumjev)

• Modification: Addition of citrate (promotes local vasodilation) + treprostinil (prostacyclin analog)
• Onset: ~10 minutes
• Time to peak: ~45 minutes
• Duration: 3–5 hours
• Clinical benefit: Reduced postprandial glucose excursions

Ultra-Rapid Comparison

Parameter	Fiasp (Aspart)	Lyumjev (Lispro)
Onset	~5 minutes	~10 minutes
Peak	~45 minutes	~45 minutes
Duration	3–5 hours	3–5 hours
Injection-meal timing	Can inject during/after meal	Can inject during/after meal

Clinical Implications

Mealtime Dosing

Standard Formulations

• Both agents: inject 10–15 minutes before meals
• Equivalent postprandial glucose control
• Can be used interchangeably (mg-for-mg)

Ultra-Rapid Formulations

• Fiasp: inject at start of meal or up to 20 minutes after
• Lyumjev: inject at start of meal or shortly after
• Better for unpredictable meal timing

Dose Equivalence

Dose	Insulin Aspart	Insulin Lispro	Notes
4 U	4 U	4 U	Equivalent
8 U	8 U	8 U	Equivalent
12 U	12 U	12 U	Equivalent
20 U	20 U	20 U	Equivalent
Maximum per injection	50–60 U	50–60 U	Volume limitation

Conversion: 1:1 unit conversion between agents at standard doses.

Specific Clinical Scenarios

Scenario	Preferred Agent	Rationale
Standard mealtime dosing	Either	Equivalent
Unpredictable meals	Ultra-rapid (Fiasp/Lyumjev)	Flexible timing
Post-meal dosing	Ultra-rapid	Better postprandial control
Continuous subcutaneous insulin infusion (CSII)	Either	Both widely used
Pediatric use	Either	Equivalent safety
Pregnancy	Lispro (more data)	Longer safety database

Safety Profile

Hypoglycemia

Parameter	Insulin Aspart	Insulin Lispro
Overall hypoglycemia rate	Comparable	Comparable
Nocturnal hypoglycemia	Comparable	Comparable
Severe hypoglycemia	Rare	Rare
Hypoglycemia unawareness	Rare	Rare

Injection Site Reactions

Reaction	Insulin Aspart	Insulin Lispro
Lipodystrophy	1–5%	1–5%
Pain	1–3%	1–3%
Bruising	2–5%	2–5%
Allergy	Very rare	Very rare

Immunogenicity

Both agents have comparable immunogenicity profiles:

• Anti-insulin antibody formation: <5%
• Clinical significance: Minimal
• Cross-reactivity: Expected (similar structure)

Storage and Handling

Parameter	Insulin Aspart	Insulin Lispro
Unopened (2–8°C)	24–30 months	24–30 months
In-use (room temp)	28 days	28 days
Maximum room temp	30°C	30°C
Freeze	Do not freeze	Do not freeze
Protect from light	Yes	Yes
shaking	Gently roll	Gently roll

Cost Considerations

Factor	Insulin Aspart	Insulin Lispro
Brand cost	Moderate-High	Moderate-High
Generic availability	Yes (since 2020)	Yes (since 2019)
Biosimilar availability	Yes	Yes
Insurance coverage	Generally covered	Generally covered
Patient assistance	Available	Available

Conclusion

Insulin aspart and insulin lispro are pharmacokinetically and pharmacodynamically equivalent rapid-acting insulin analogs. Their onset times (10–20 minutes), peak effects (1–2 hours), and durations of action (3–5 hours) are essentially identical. The choice between agents should be based on formulation preference, availability of ultra-rapid formulations (Fiasp for aspart, Lyumjev for lispro), patient familiarity, and cost considerations rather than pharmacokinetic differences. Both are appropriate for mealtime dosing with 1:1 dose conversion.